MacroGenics 将来の成長
Future 基準チェック /06
MacroGenicsの収益は年間12.8%で減少すると予測されていますが、年間収益は年間8.8%で増加すると予想されています。EPS は年間8.3%で減少すると予想されています。
主要情報
-12.8%
収益成長率
-8.29%
EPS成長率
| Biotechs 収益成長 | 25.3% |
| 収益成長率 | 8.8% |
| 将来の株主資本利益率 | n/a |
| アナリストカバレッジ | Low |
| 最終更新日 | 14 May 2026 |
今後の成長に関する最新情報
Recent updates
ナラティブの更新 • Jun 23
MGNX: Tubulus Deal Optimism Will Likely Outpace Real Execution Progress
Analysts have raised their price target on MacroGenics by $2, citing updated assumptions regarding fair value, discount rate, revenue growth, profit margin, and future P/E following recent research and deal commentary. Analyst Commentary Recent research on MacroGenics reflects a mix of interest in the story and caution around what is already priced into the stock.
ナラティブの更新 • Jun 05
MGNX: Antibody Drug Conjugate Data And Deals Will Drive Future Upside
Narrative Update: MacroGenics Analysts have raised their price targets on MacroGenics by $1 to $2, citing updated views on the company's antibody drug conjugate potential and recent deal activity as key reasons for the higher valuation outlook. Analyst Commentary Recent Street research on MacroGenics has focused on price target changes, rating shifts and the role of the antibody drug conjugate pipeline in shaping expectations for future execution and potential valuation outcomes.ナラティブの更新 • May 21
MGNX: Antibody Drug Conjugate Progress Will Drive Future Upside Potential
Analysts have lifted their price target on MacroGenics to $6.75 from $3.75, citing updated assumptions on revenue trends, profitability and a lower expected P/E multiple, as well as recent positive research following the Tubulis deal and ongoing antibody drug conjugate progress. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher price targets as a reflection of updated assumptions on revenue trends and profitability, suggesting they see the current valuation as more aligned with their revised models.
ナラティブの更新 • Apr 26
MGNX: Antibody Drug Conjugate Pipeline And 2026 Data Will Drive Repricing
Narrative Update on MacroGenics Analysts have raised their price targets on MacroGenics by $2 to $4. They cite updated revenue assumptions and interest in the company’s antibody drug conjugate pipeline as key factors behind the change.ナラティブの更新 • Apr 12
MGNX: Antibody Drug Conjugate Pipeline And Tubulus Deal Will Drive Repricing
Analysts raised their price target for MacroGenics from $5.00 to $9.00, citing updated assumptions for potential revenue growth, slightly higher profit margins, a lower discount rate and recent positive sentiment following the Tubulus deal and the outlook for antibody-drug conjugate data. Analyst Commentary Bullish analysts are pointing to recent research updates as a sign that expectations for MacroGenics are shifting toward a more constructive view, with price targets and ratings adjusted to reflect changing assumptions around future execution and potential revenue streams.Seeking Alpha • Apr 10
MacroGenics: Oncology Opportunities In Play, But Investing Feels Like A Gamble
Summary MacroGenics (MGNX) is rated Hold, reflecting significant upside potential but high risk and a limited funding runway beyond 2027. MGNX’s pipeline includes antibody drug conjugates and lorigerlimab, with the latter’s Phase 2 clinical hold recently lifted by the FDA. Key 2026 catalysts include clinical data from MGC026, MGC028, and the LINNET study, plus an IND submission for MGC030. Despite past setbacks and a $190m cash position, MGNX’s current valuation implies little pipeline value, making study success critical for future funding. Read the full article on Seeking Alpha分析記事 • Jan 06
There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues Despite A 26% Share Price Rise
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders are no doubt pleased to see that the share price has bounced 26% in the...ナラティブの更新 • Sep 25
LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks
The consensus analyst price target for MacroGenics increased to $3.75, primarily reflecting a higher expected future P/E multiple despite a decline in net profit margin. What's in the News Eric Risser appointed Chief Executive Officer, succeeding long-time CEO Scott Koenig; Risser has extensive company and industry experience, having led corporate development efforts that generated $1.6 billion in non-dilutive capital.分析記事 • Sep 08
MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 30% But Its Business Prospects Need A Lift Too
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders would be excited to see that the share price has had a great month...ナラティブの更新 • Aug 16
LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks
Despite an improving net profit margin and a sharply lower future P/E multiple reflecting more attractive valuation, the consensus analyst price target for MacroGenics has been notably reduced from $4.20 to $3.40. What's in the News Eric Risser appointed CEO, succeeding longtime leader Scott Koenig; Risser brings significant operational and business development experience, including generating over $1.6 billion in non-dilutive capital for the company.分析記事 • Jul 24
MacroGenics, Inc. (NASDAQ:MGNX) Surges 37% Yet Its Low P/S Is No Reason For Excitement
MacroGenics, Inc. ( NASDAQ:MGNX ) shares have had a really impressive month, gaining 37% after a shaky period...分析記事 • May 21
Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders will have a reason to smile today, with the analysts making substantial...分析記事 • Apr 14
MacroGenics, Inc. (NASDAQ:MGNX) Looks Inexpensive After Falling 42% But Perhaps Not Attractive Enough
Unfortunately for some shareholders, the MacroGenics, Inc. ( NASDAQ:MGNX ) share price has dived 42% in the last thirty...
新しいナラティブ • Apr 02
LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks
Future revenue growth potential hinges on successful trial outcomes and product approvals in ongoing and upcoming clinical studies.分析記事 • Feb 28
MacroGenics, Inc. (NASDAQ:MGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%
Unfortunately for some shareholders, the MacroGenics, Inc. ( NASDAQ:MGNX ) share price has dived 26% in the last thirty...Seeking Alpha • Feb 27
MacroGenics: Stacking Up A Lot Of Headwinds... But It's Fallen Too Far
Summary MacroGenics' valuation has declined due to continued bad news in 2024, impacting market sentiment. MGNX holds $179.6M in cash and equivalents, with a sustainable cash burn rate for up to 5 years. Sale of the margetuximab franchise poises the company for further financial stability. Operating expenses are expected to rise as clinical programs advance, with management projecting a cash runway into 2026. I think this is a conservative estimate. Although a lot has changed, I think these price levels are attractive for a tentative investment based on catalysts I anticipate in 2025 and beyond. Read the full article on Seeking AlphaSeeking Alpha • Dec 05
MacroGenics: A Productive Biotech With Growing Potential - Still Not A Buy
Summary MacroGenix was previously rated as a "Hold" due to uncertain revenue streams and high annual expenses of ~$300 million. Since the initial rating, MacroGenix's stock has dropped approximately 33%, reflecting ongoing financial challenges. The company's reliance on episodic milestones and minimal product revenues makes it unattractive for new investors. Existing investors might accept the risk, but the current financial outlook remains unattractive for prospective buyers. Read the full article on Seeking Alpha分析記事 • Aug 01
Party Time: Brokers Just Made Major Increases To Their MacroGenics, Inc. (NASDAQ:MGNX) Earnings Forecasts
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders will have a reason to smile today, with the analysts making substantial...分析記事 • Jul 30
MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders are no doubt pleased to see that the share price has bounced 29% in the...分析記事 • Jul 12
We're A Little Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...分析記事 • May 13
MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders that were waiting for something to happen have been dealt a blow with a...Seeking Alpha • May 13
MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)
Summary Macrogenics' stock valuation has dropped over 70% after its first quarter update, creating a new opportunity for investors. The spotlight is on their product vobramitamab duocarmazine, and the phase 2 TAMARACK trial. Macrogenics has between 4 and 5 quarters of cash and investments on hand. Read the full article on Seeking AlphaSeeking Alpha • Apr 05
MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024
Summary Positive safety update released from phase 2 TAMARACK study, using vobra duo for the treatment of patients with metastatic castration-resistant prostate cancer. Updates to interim data from the phase 2 TAMARACK study expected by May 31st of 2024. Radiographic progression-free survival data from the phase 2 TAMARACK study, expected by fall of 2024. The global prostate cancer market size is estimated to reach $27.51 billion by 2032. Read the full article on Seeking Alpha分析記事 • Feb 28
MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Despite an already strong run, MacroGenics, Inc. ( NASDAQ:MGNX ) shares have been powering on, with a gain of 27% in...Seeking Alpha • Feb 15
MacroGenics: Trying To Build A Better Everything
Summary MacroGenics, Inc. has a pipeline of promising drugs including Vobramitamab Duocarmazine, Lorigerlimab, Tebotelimab, MGD024, and IMGC936. The company has a strong financial position as of their latest report. MacroGenics faces both strengths and risks in their drug development and commercialization efforts. Read the full article on Seeking Alpha業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2028 | 135 | -168 | -136 | N/A | 3 |
| 12/31/2027 | 94 | -127 | -145 | N/A | 5 |
| 12/31/2026 | 164 | -18 | 25 | N/A | 4 |
| 3/31/2026 | 157 | -70 | -72 | -70 | N/A |
| 12/31/2025 | 150 | -75 | -83 | -81 | N/A |
| 9/30/2025 | 128 | -76 | -165 | -162 | N/A |
| 6/30/2025 | 165 | -36 | -75 | -72 | N/A |
| 3/31/2025 | 154 | -56 | -72 | -70 | N/A |
| 12/31/2024 | 150 | -67 | -72 | -68 | N/A |
| 9/30/2024 | 141 | -98 | -62 | -58 | N/A |
| 6/30/2024 | 41 | -136 | -157 | -153 | N/A |
| 3/31/2024 | 43 | -23 | -114 | -111 | N/A |
| 12/31/2023 | 59 | -9 | -80 | -78 | N/A |
| 9/30/2023 | 121 | 50 | -22 | -21 | N/A |
| 6/30/2023 | 152 | 7 | 3 | 5 | N/A |
| 3/31/2023 | 165 | -91 | -45 | -42 | N/A |
| 12/31/2022 | 152 | -120 | -91 | -87 | N/A |
| 9/30/2022 | 93 | -191 | -175 | -171 | N/A |
| 6/30/2022 | 67 | -219 | -182 | -176 | N/A |
| 3/31/2022 | 72 | -217 | -179 | -172 | N/A |
| 12/31/2021 | 77 | -202 | -150 | -144 | N/A |
| 9/30/2021 | 116 | -146 | -103 | -95 | N/A |
| 6/30/2021 | 119 | -129 | -113 | -106 | N/A |
| 3/31/2021 | 108 | -136 | -102 | -97 | N/A |
| 12/31/2020 | 105 | -130 | -118 | -112 | N/A |
| 9/30/2020 | 77 | -158 | -148 | -144 | N/A |
| 6/30/2020 | 78 | -167 | -140 | -136 | N/A |
| 3/31/2020 | 68 | -152 | -152 | -148 | N/A |
| 12/31/2019 | 64 | -152 | N/A | -134 | N/A |
| 9/30/2019 | 55 | -166 | N/A | -123 | N/A |
| 6/30/2019 | 57 | -155 | N/A | -143 | N/A |
| 3/31/2019 | 65 | -167 | N/A | -152 | N/A |
| 12/31/2018 | 60 | -171 | N/A | -153 | N/A |
| 9/30/2018 | 197 | -21 | N/A | -14 | N/A |
| 6/30/2018 | 178 | -34 | N/A | -9 | N/A |
| 3/31/2018 | 160 | -32 | N/A | 18 | N/A |
| 12/31/2017 | 158 | -20 | N/A | 14 | N/A |
| 9/30/2017 | 10 | -160 | N/A | -126 | N/A |
| 6/30/2017 | 12 | -147 | N/A | -45 | N/A |
| 3/31/2017 | 91 | -66 | N/A | -47 | N/A |
| 12/31/2016 | 92 | -59 | N/A | -44 | N/A |
| 9/30/2016 | 95 | -52 | N/A | -40 | N/A |
| 6/30/2016 | 106 | -34 | N/A | -97 | N/A |
| 3/31/2016 | 32 | -96 | N/A | -89 | N/A |
| 12/31/2015 | 101 | -20 | N/A | -14 | N/A |
| 9/30/2015 | 98 | -11 | N/A | -10 | N/A |
| 6/30/2015 | 102 | 1 | N/A | -16 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: MGNX今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: MGNX今後 3 年間、利益が出ない状態が続くと予測されています。
高成長収益: MGNX今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: MGNXの収益 ( 8.8% ) US市場 ( 12.7% ) よりも低い成長が予測されています。
高い収益成長: MGNXの収益 ( 8.8% ) 20%よりも低い成長が予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: MGNXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/06/26 22:26 |
| 終値 | 2026/06/26 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
MacroGenics, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。17
| アナリスト | 機関 |
|---|---|
| Etzer Darout | Barclays |
| Peter Lawson | Barclays |
| Stephen V. Byrne | BofA Global Research |